To further investigate whether JNK/JUN signaling was activated by the combination therapy, we analyzed melanoma cells for JNK phosphorylation and JUN accumulation following treatment with trametinib and CuET by Western blotting (Fig. 5A). This evidence concerns the gene MAPK8 and melanoma.